Bookmark
Forward
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma.
Cancer discovery 2020 MaySizes of these terms reflect their relevance to your search.
The FGFR2b inhibitor bemarituzumab was effective in high-FGFR2b gastroesophageal adenocarcinoma. ©2020 American Association for Cancer Research.
Citation
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma. Cancer discovery. 2020 May;10(5):638
Mesh Tags
Substances
PMID: 32220925
View Full Text
